O aumento da expectativa de vida da população mundial tem se associado com uma maior prevalência de doenças neurodegenerativas. A Doença de Alzheimer (DA) é a doença neurodegenerativa mais comum e a principal causa de demência em indivíduos com mais de 60 anos, sendo caracterizada por um declínio progressivo na memória e função mental dos pacientes. Esses sintomas são acompanhados por alterações histopatológicas no cérebro desses indivíduos, incluindo a presença de uma grande quantidade de placas senis, formadas pela deposição do peptídeo beta-amiloide (Aβ), e de emaranhados neurofibrilares formados pela hiperfosforilação da proteína Tau. Estudos indicam que a deposição do Aβ é uma das principais responsáveis pelo desenvolvimento da DA, causando dano neuronal através da ativação de várias vias pró-apoptóticas e dando origem aos sintomas de demência típicos dessa doença. Até o momento, não existem tratamentos eficazes para o combate à DA, de forma que a maior parte das intervenções farmacológicas é destinada apenas ao tratamento de alguns de seus sintomas. A proteína translocadora (TSPO) se localiza em pontos de contato entre as membranas mitocondriais interna e externa e está relacionada com o transporte de colesterol para o interior da mitocôndria e com a regulação da esteroidogênese e da apoptose. Estudos mostram que ligantes da TSPO apresentam efeitos neuroprotetores em diferentes modelos experimentais de lesão cerebral e doenças neurodegenerativas. Especificamente em relação à DA, um estudo indicou que o 4’-clorodiazepam (4’-CD), um ligante da TSPO, apresenta efeitos neuroprotetores em um modelo animal dessa doença, sendo um possível candidato para o seu tratamento. Dessa forma, o objetivo desse estudo foi verificar o efeito neuroprotetor do 4’-CD em diferentes modelos in vitro de toxicidade induzida pelo Aβ, além de seus efeitos sobre o desenvolvimento de neurônios hipocampais. Inicialmente, demonstramos que o 4’-CD reduziu a morte celular de células SH-SY5Y expostas a um modelo de toxicidade induzida pela administração de Aβ. Esses efeitos estiveram associados com a redução da expressão da proteína pró-apoptótica Bax e com um aumento da expressão da survivina, uma proteína anti-apoptótica. A expressão das proteínas Bcl-xl e procaspase-3, por outro lado, não foi alterada pelos tratamentos. Posteriormente, estudamos os efeitos neuroprotetores do 4’-CD contra a toxicidade induzida pela administração do Aβ em culturas organotípicas de hipocampo. Nesses experimentos, foi demonstrado que o 4’-CD reduz a morte celular de culturas organotípicas de hipocampo expostas ao Aβ através de um aumento na expressão da enzima SOD, sem alterar, no entanto, a expressão das proteínas Akt e procaspase-3. Por fim, foi avaliado o efeito do 4’-CD sobre o desenvolvimento de culturas primárias de neurônios hipocampais de camundongos machos e fêmeas. Foi observado que as culturas de neurônios hipocampais das fêmeas apresentaram um desenvolvimento mais rápido do que as dos machos. O 4’-CD acelerou a maturação e aumentou a ramificação neurítica dos neurônios hipocampais dos machos, mas não exerceu qualquer efeito sobre os neurônios das fêmeas. Em suma, foi observado que o 4’-CD apresenta efeitos neuroprotetores contra o Aβ em células SH-SY5Y e em culturas organotípicas do hipocampo, apresentando-se como um fármaco em potencial para o tratamento da DA. Além disso, foi observado que o 4’-CD exerceu um efeito dependente do sexo sobre o desenvolvimento de culturas primárias de neurônios hipocampais, estimulando o desenvolvimento e a ramificação neurítica de neurônios hipocampais de machos, mas não de fêmeas. / The increase in life expectancy of the world population has been associated with a higher prevalence of neurodegenerative diseases. The Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the main cause of dementia among people over 60 years, being characterized by a progressive decline in the memory and mental function of the patients. These symptoms are associated with histopathological changes in the brain of these patients, including the presence of senile plaques, formed by the deposition of amyloid-beta (Aβ), and neurofibrillary tangles, which are related to the hyperphosphorylation of Tau protein. Studies indicate that Aβ deposition is a major contributor to AD progression, promoting neuronal damage through the activation of different pro-apoptotic pathways and giving rise to the typical dementia symptoms of this disease. To date, there are no effective treatments for AD, so that most of the pharmacological intervention is intended for the treatment of some of its symptoms. The translocator protein (TSPO) is located in contact sites between the outer and the inner mitochondrial membranes and is involved in the cholesterol transport into the mitochondria and in the regulation of steroidogenesis and apoptosis. Studies show that TSPO ligands present neuroprotective effects in different experimental models of brain injury and neurodegenerative diseases. Specifically regarding AD, a study indicated that 4’-chlorodiazepam (4’-CD), a TSPO ligand, is neuroprotective in an animal model of this disease, being a possible candidate for its treatment. Therefore, the aim of this study was to evaluate the neuroprotective effect of 4’-CD in different experimental models of Aβ- induced neurotoxicity in vitro, as well as its effects on the development of hipocampal neurons. First, it was demonstrated that 4’-CD decreased the cell death of SH-SY5Y cells exposed to the Aβ. This effect was associated with the inhibition of the Aβ-induced upregulation of Bax, a pro-apoptotic protein, and downregulation of survivin, a prosurvival protein. On the other hand, the expression of Bcl-xl and procaspase-3 was not change by the treatments. After, it was studied the neuroprotective effects of 4’-CD against Aβ in organotypic hipocampal cultures. In these experiments, it was shown that 4’-CD decreases the cell death of organotypic hippocampal slices exposed to the Aβ by increasing the protein expression of SOD, but without changing the expression of Akt and procaspase-3. Finally, due to the importance of the processes of neuronal development and maturation in the regeneration of CNS after injury, it was evaluated the effect of 4’-CD on the development of primary hippocampal neurons of male and female mice. It was observed that female primary hippocampal neurons presented an increased rate of development than male neurons. 4’-CD stimulated the development and increased the neuritic branching of male but not from female neurons. In summary, it was observed that 4’-CD presented a neuroprotective effect against Aβ in SH-SY5Y cells and in rat organotypical hippocampal slices, presenting itself as a promising agent for the treatment of AD. Also, it was observed that 4’-CD modulates the development of hippocampal neurons in a sex-dependent manner, stimulating the development of male but not from female cells.

O aumento da expectativa de vida da população mundial tem se associado com uma maior prevalência de doenças neurodegenerativas. A Doença de Alzheimer (DA) é a doença neurodegenerativa mais comum e a principal causa de demência em indivíduos com mais de 60 anos, sendo caracterizada por um declínio progressivo na memória e função mental dos pacientes. Esses sintomas são acompanhados por alterações histopatológicas no cérebro desses indivíduos, incluindo a presença de uma grande quantidade de placas senis, formadas pela deposição do peptídeo beta-amiloide (Aβ), e de emaranhados neurofibrilares formados pela hiperfosforilação da proteína Tau. Estudos indicam que a deposição do Aβ é uma das principais responsáveis pelo desenvolvimento da DA, causando dano neuronal através da ativação de várias vias pró-apoptóticas e dando origem aos sintomas de demência típicos dessa doença. Até o momento, não existem tratamentos eficazes para o combate à DA, de forma que a maior parte das intervenções farmacológicas é destinada apenas ao tratamento de alguns de seus sintomas. A proteína translocadora (TSPO) se localiza em pontos de contato entre as membranas mitocondriais interna e externa e está relacionada com o transporte de colesterol para o interior da mitocôndria e com a regulação da esteroidogênese e da apoptose. Estudos mostram que ligantes da TSPO apresentam efeitos neuroprotetores em diferentes modelos experimentais de lesão cerebral e doenças neurodegenerativas. Especificamente em relação à DA, um estudo indicou que o 4’-clorodiazepam (4’-CD), um ligante da TSPO, apresenta efeitos neuroprotetores em um modelo animal dessa doença, sendo um possível candidato para o seu tratamento. Dessa forma, o objetivo desse estudo foi verificar o efeito neuroprotetor do 4’-CD em diferentes modelos in vitro de toxicidade induzida pelo Aβ, além de seus efeitos sobre o desenvolvimento de neurônios hipocampais. Inicialmente, demonstramos que o 4’-CD reduziu a morte celular de células SH-SY5Y expostas a um modelo de toxicidade induzida pela administração de Aβ. Esses efeitos estiveram associados com a redução da expressão da proteína pró-apoptótica Bax e com um aumento da expressão da survivina, uma proteína anti-apoptótica. A expressão das proteínas Bcl-xl e procaspase-3, por outro lado, não foi alterada pelos tratamentos. Posteriormente, estudamos os efeitos neuroprotetores do 4’-CD contra a toxicidade induzida pela administração do Aβ em culturas organotípicas de hipocampo. Nesses experimentos, foi demonstrado que o 4’-CD reduz a morte celular de culturas organotípicas de hipocampo expostas ao Aβ através de um aumento na expressão da enzima SOD, sem alterar, no entanto, a expressão das proteínas Akt e procaspase-3. Por fim, foi avaliado o efeito do 4’-CD sobre o desenvolvimento de culturas primárias de neurônios hipocampais de camundongos machos e fêmeas. Foi observado que as culturas de neurônios hipocampais das fêmeas apresentaram um desenvolvimento mais rápido do que as dos machos. O 4’-CD acelerou a maturação e aumentou a ramificação neurítica dos neurônios hipocampais dos machos, mas não exerceu qualquer efeito sobre os neurônios das fêmeas. Em suma, foi observado que o 4’-CD apresenta efeitos neuroprotetores contra o Aβ em células SH-SY5Y e em culturas organotípicas do hipocampo, apresentando-se como um fármaco em potencial para o tratamento da DA. Além disso, foi observado que o 4’-CD exerceu um efeito dependente do sexo sobre o desenvolvimento de culturas primárias de neurônios hipocampais, estimulando o desenvolvimento e a ramificação neurítica de neurônios hipocampais de machos, mas não de fêmeas. / The increase in life expectancy of the world population has been associated with a higher prevalence of neurodegenerative diseases. The Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the main cause of dementia among people over 60 years, being characterized by a progressive decline in the memory and mental function of the patients. These symptoms are associated with histopathological changes in the brain of these patients, including the presence of senile plaques, formed by the deposition of amyloid-beta (Aβ), and neurofibrillary tangles, which are related to the hyperphosphorylation of Tau protein. Studies indicate that Aβ deposition is a major contributor to AD progression, promoting neuronal damage through the activation of different pro-apoptotic pathways and giving rise to the typical dementia symptoms of this disease. To date, there are no effective treatments for AD, so that most of the pharmacological intervention is intended for the treatment of some of its symptoms. The translocator protein (TSPO) is located in contact sites between the outer and the inner mitochondrial membranes and is involved in the cholesterol transport into the mitochondria and in the regulation of steroidogenesis and apoptosis. Studies show that TSPO ligands present neuroprotective effects in different experimental models of brain injury and neurodegenerative diseases. Specifically regarding AD, a study indicated that 4’-chlorodiazepam (4’-CD), a TSPO ligand, is neuroprotective in an animal model of this disease, being a possible candidate for its treatment. Therefore, the aim of this study was to evaluate the neuroprotective effect of 4’-CD in different experimental models of Aβ- induced neurotoxicity in vitro, as well as its effects on the development of hipocampal neurons. First, it was demonstrated that 4’-CD decreased the cell death of SH-SY5Y cells exposed to the Aβ. This effect was associated with the inhibition of the Aβ-induced upregulation of Bax, a pro-apoptotic protein, and downregulation of survivin, a prosurvival protein. On the other hand, the expression of Bcl-xl and procaspase-3 was not change by the treatments. After, it was studied the neuroprotective effects of 4’-CD against Aβ in organotypic hipocampal cultures. In these experiments, it was shown that 4’-CD decreases the cell death of organotypic hippocampal slices exposed to the Aβ by increasing the protein expression of SOD, but without changing the expression of Akt and procaspase-3. Finally, due to the importance of the processes of neuronal development and maturation in the regeneration of CNS after injury, it was evaluated the effect of 4’-CD on the development of primary hippocampal neurons of male and female mice. It was observed that female primary hippocampal neurons presented an increased rate of development than male neurons. 4’-CD stimulated the development and increased the neuritic branching of male but not from female neurons. In summary, it was observed that 4’-CD presented a neuroprotective effect against Aβ in SH-SY5Y cells and in rat organotypical hippocampal slices, presenting itself as a promising agent for the treatment of AD. Also, it was observed that 4’-CD modulates the development of hippocampal neurons in a sex-dependent manner, stimulating the development of male but not from female cells.

A Doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva que causa comprometimento cognitivo em idosos. O diagnóstico clínico da DA é complexo. Existe uma grande necessidade de técnicas capazes de detectar a doença nos estágios iniciais, tanto para auxiliar o diagnóstico quanto para monitorar a efetividade dos tratamentos disponíveis. As alterações bioquímicas da DA são resultado de processos celulares como o metabolismo da proteína precursora do amilóide (APP), fosforilação da tau, stress oxidativo, inflamação e desregulação lipídica. Até o momento não existem marcadores bioquímicos para auxiliar o diagnóstico da DA. Este trabalho avaliou três possíveis candidatos a marcadores bioquímicos para a DA. Foram investigados a razão da APP (rAPP) de 130/110 kDa, fluidez de membrana e atividade da fosfolipase A2 em plaquetas de pacientes com DA e Comprometimento Cognitivo Leve (CCL), comparando-se seus resultados com controles idosos saudáveis. A fluidez das membranas das plaquetas foi avaliada por meio da anisotropia com a sonda fluorescente DPH (Difenilhexatrieno); a comparação das razões da APP foi realizada por Western Blotting empregando o anticorpo 22C11 e a da atividade da PLA2 foi determinada por ensaio radioenzimático com substratos e concentrações de cálcio específicas para cada um dos três principais grupos da enzima. A rAPP, as atividades da sPLA2 e iPLA2 estavam significantemente reduzidas na DA quando comparadas com controles, enquanto que a cPLA2 e a fluidez de membrana não apresentaram diferenças entre os grupos. A rAPP e a iPLA2 também apresentaram diferenças significativas entre CCL e DA, além de estarem correlacionadas com os parâmetros cognitivos MEEM e CAMCOG. A rAPP também estava correlacionada com a anistropia do DPH. / Alzheimer disease (AD) is a progressive neurodegenerative disorder that causes cognitive impairment in the elderly. The clinical diagnosis of AD is complex. Thus, there is a great need for sensitive techniques to detect neurodegeneration in the early stages to asset in the diagnosis and to follow the effectiveness of therapy. The biochemical alterations in the AD brain result from cellular processes such as amyloid precursor protein (APP) metabolism, tau phosphorylation, oxidative stress, inflammation and lipid dysregulation. So far there are no biochemical markers to help the AD diagnosis. The purpose of this study was to evaluate three possible candidates to biochemical marker of AD. The APP 130/110 kDa ratio, membrane fluidity and phospholipase A2 activity in platelets of patients with AD and mild cognitive impairment (MCI) were investigated compared to their results with healthy elderly controls. The membrane fluidity of platelets was assessed by the fluorescence anisotropy of DPH (diphenyl-hexatriene); the levels of APP isoforms were evaluated by Western Blot analysis using 22C11 antibody and the PLA2 activity was measured by radio-enzymatic assay with enzyme specific substrate and calcium concentrations for each one of the three main groups of the enzyme. The APP ratio (APPr), the sPLA2 and iPLA2 activity were markedly decreased in AD in comparing with controls, whereas a cPLA2 and membrane fluidity didn\'t show any alteration between the groups evaluated. The APPr and iPLA2 also showed significant differences between MCI e AD, and were correlated with cognitive parameters MMSE and CAMCOG. The APPr was also correlated with DPH anisotropy.

A neurodegeneração é um processo onde ocorre morte celular progressiva. O tráfego neuronal anterógrado e retrógado, e entre os compartimentos é essencial para a viabilidade celular. As proteínas Rabs pertencem à família de pequenas GTPases, com funções de tráfego de vesículas e organelas, para realizarem sua função as proteínas Rab podem recrutar proteínas motoras como as KIF 1B e KIF 5, responsáveis pelo transporte anterógrado mitocondrial. A associação do distúrbio do tráfego intracelular com doenças neurodegenerativas tem sido tema de estudos recentes. Com isso o objetivo do presente trabalho é analisar a expressão das proteínas Rab, bem como estudar as proteínas motoras que podem contribuir para o esclarecimento sobre os distúrbios no tráfego intracelular que antecedem a formação de agregados proteicos envolvidos em neurodegeneração. Para tanto, utilizou-se o modelo de tratamento com rotenona para indução de agregados em Ratos Lewis idosos que foram expostos a rotenona durante 4 semanas, em seguida foram avaliados os níveis de expressão das proteínas Rab no hipocampo, substância negra e locus coeruleus, por western blotting. Foram analisados também os níveis de expressão das proteínas motoras KIF1B e KIF5 antes e durante a formação de agregados proteicos, em culturas de células, de ratos Lewis neonatos, do hipocampo, substância negra e locus coeruleus tratadas com rotenona por 24 horas ou 48 horas nas concentrações de 0,1nM, 0, 3nM e 0,5nM. Foi observado diminuição dos níveis de expressão das proteínas Rab 1 nas regiões do hipocampo e locus coeruleus. Houve aumento de expressão das Rab 4,5 e 6 no hipocampo, porém na substância negra a expressão da Rab 1 aumentou e da Rab 6 diminuiu. Já no locus coeruleus in vivo a Rab 6 aumentou, mas as Rab 1, 5 e 11 diminuíram sua expressão. Já a expressão da KIF 5 aumentou com o tratamento de 0,1nM de rotenona e diminuiu após 0,5nM do xenobiótico por 48 horas in vitro, na mesma região. Na substância negra aumentaram as KIFs 1B e 5 após o tratamento com 0,5nM por 48 horas in vitro, mas diminuíram as KIF 1B e 5 após o tratamento com 0,3nM por 24 horas e KIF 5 após o tratamento com 0,1nM por 48 horas. Esses resultados permitem concluir que a expressão de proteínas importantes para o tráfego mitocondrial e de vesículas encontram-se alteradas e fazem parte dos eventos intracelulares que antecedem a neurodegeneração / Neurodegeneration is a process that leads to progressive cell death. The anterograde and retrograde neuronal traffic as well as the traffic between compartments are essential for cell viability. The Rab proteins belong to the small GTPases family with function of vesicles and organelle trafficking. Rab proteins can recruit motor proteins such as KIF 1B and KIF 5 that are responsible for anterograde mitochondrial transport. The association of intracellular traffic disturb with neurodegenerative diseases have been theme of recent studies. Thereat the objective of this study is analyze the expression of Rab and motor proteins that can contribute for the understanding about the disturb of the intracellular traffic that precedes protein aggregation involved in neurodegeneration. For this purpose it was employed the model of rotenone treatment for induction of aggregation in aged Lewis rats that were exposed to rotenone during 4 weeks in order to evaluate Rabs expression. The levels of motor proteins KIF 1B and KIF 5 expression were evaluated before and during the formation of protein aggregates in hippocampus, substantia nigra and locus coeruleus cell cultures of neonates Lewis rats, exposed to rotenone for 24 hours or 48 hours in the concentrations of 0.1nM, 0.3nM or 0.5nM. It was observed decreased levels of Rab 1 expression in hippocampus and locus coeruleus. Rabs 4,5 and 6 were increased in the hippocampus, but in the substantia nigra the expression of Rab 1 increased and Rab 6 decreased. In the locus coeruleus the Rab 6 increased, but Rabs 1, 5 and 11 decreased. The expression of KIF 5 increased after 0.1nM of rotenone and decreased after the exposure to 0.5nM of for 48 hours in cultured cell from the locus coeruleus. In the substantia nigra the KIF1B and KIF 5 increased after treatment with 0.5nM for 48 hours in vitro, but these protein decreased after treatment with 0.3nM for 24 hours in vitro, and KIF 5 after treatment with 0.1nM for 48 hours. These results allow us conclude that the expression of important proteins for the mitochondrial and vesicles traffic are altered and participate of intracellular events that precede the neurodegeneration

A Doença de Alzheimer (DA) é o tipo mais comum de demência em idosos, a etiologia é multifatorial e a fisiopatologia da doença é complexa, com um novo caso acontecendo a cada sete segundos; globalmente, a doença está se tornando em uma lenta pandemia. Bioquimicamente, a DA é caracterizada pela presença das placas neuríticas (PNs) e os novelos neurofibrilares (NNFs). O peptídeo beta peptide1-42 (A?(1-42)) é o principal componente das placas neuríticas e tem sido fortemente associado ao estresse oxidativo, desregulação colinérgica e morte celular. Os múltiplos mecanismos envolvidos na patogênese criam consideráveis dificuldades para identificar alvos terapêuticos apropriados. As abordagens terapêuticas atuais melhoram temporariamente os sintomas da DA; no entanto, apesar de esforços intensivos, nenhum dos tratamentos disponíveis hoje conseguiu alterar o curso da doença. Porém, algumas das terapias mais relevantes para o tratamento da doença estão baseadas na atividade inibidora da acetilcolinesterase (AChE). Nos últimos anos, os alcaloides pertencentes à família Amaryllidaceae têm recebido muita atenção devido à atividade anticolinérgica e antioxidante. A galantamina foi o primeiro alcaloide isolado a partir de diferentes espécies de Amaryllidaceas e é o mais recente inibidor da AChE aprovado para o tratamento sintomático da DA. Este fato tem motivado a pesquisa de outros alcaloides como possíveis moduladores da doença em adição à atividade inibitória da AChE. Diante disso, o objetivo deste estudo foi investigar se o extrato de Caliphruria subedentata e a galantamina modulam a neurotoxicidade induzida pelo A?(1-42) na linhagem celular SH-SY5Y indiferenciada. Para compreender os mecanismos de neuroproteção, um conjunto de ensaios foi realizado tais como atividade inibitória da AChE, ensaios clonogênico, micronúcleos com bloqueio na citocinese celular (CBMNcyt), cometa; análises por microscopia eletrônica de transmissão (MET) e de metilação. Os resultados mostraram que tanto o extrato quanto a galantamina diminuíram significativamente a citotoxicidade e genotoxicidade induzida pelo A?(1-42). Além disso, ambos os tratamentos modularam alterações morfológicas mitocondriais induzidas pelo peptídeo. Em conclusão, os resultados deste estudo demonstraram que, em adição à atividade inibitória da AChE, tanto o extrato de C. subedentata quanto a galantamina exercem propriedades antigenotóxicas. Essas propriedades relevantes da Amaryllidaceaes e o fármaco tornam-se um potencial valioso para continuar sendo explorado. / Alzheimer´s disease (AD) is the most common type of dementia in elderly population, the etiology is multifactorial and the pathophysiology of the disease is complex, with a new case occurring every seven seconds; globally, the disease itself is becoming a slowly pandemic. Biochemically, the AD is characterized by presence of the neuritic plaques and neurofibrillary tangles. Amyloid beta peptide1-42 (A?(1-42)) is the principal component of neuritic plaques and it has been strongly associated with oxidative stress, cholinergic deregulation and cell death. The multiple mechanisms involved in the pathogenesis create considerable difficulty to identify appropriate targets. The current therapeutics approaches for AD improve temporally the symptoms; and despite intensive efforts, none of the treatments available today alter the course of disease. Nervertheless, some of the most relevant therapies for the treatment of disease are based on acetylcholinesterase (AChE) inhibitor activity. In recent years, alkaloids belonging Amaryllidaceae family have received great attention due to the well-known anticholinergic and antioxidant activity and the galanthamine was the first alkaloid isolated from different species of Amaryllidacea and it is the most recently AChE inhibitor approved for the symptomatic treatment of AD. This fact has motivated the screening of other alkaloids as possible modulators of disease in addition acetylcholinesterase activity. Purpose this study was to investigate whether C. subedentata extract and galanthamine modulate A?(1-42)- induced neurotoxicity in the undifferentiated SH-SY5Y cell line. To understand the mechanisms of the neuroprotection, a set of biomarkers such as AChE activity, clonogenic, cytokinesis block micronucleus cytome (CBMNcyt) and comet assays; beside transmission electron microscope (TEM) and methylation analyses were realized. The results showed that C. subedentata extract and galanthamine were capable to significantly reduce the A?(1-42)- induced cytotoxicity and genotoxicity. Furthermore both treatments modulated A?(1-42)- induced mitochondrial morphological alterations. In conclusion, this study demonstrated that in addition to inhibition of acetylcholinesterase (AChE), the extract of C. subedentata and galanthamine exert antigenotoxic properties. This relevant property of Amaryllidaceaes and galanthamine are worthwhile exploring further which may improve the development of new diseases-modifying agents.

La maladie d’Alzheimer (MA) est un désordre neuro-dégénératif chronique fatal et la forme la plus répandue des démences chez l’adulte qui touchent plus de 28 millions de personnes dans le monde. En absence de traitement pour les démences neurodégénérative dont la maladie d’Alzheimer, le coût de celles-ci est estimé à 1 trillion d’USD en 2018 ce qui représente des enjeux économiques et sociétaux majeurs au niveau national et mondial. La MA est une forme d’amylose qui est caractérisée par l’agrégation du peptide amyloïde beta (Aβ) dans le cerveau des patients. Le facteur de risque génétique principal de la forme tardive (après 65 ans) de cette maladie est l’isoforme E4 de l’apolipoprotéine E (apoE) qui intervient dans le transport et le métabolisme des lipides et interagit avec le peptide Aβ. La modulation de la structure des isoformes d’apoE et de leur interaction avec l’Aβ apparaît comme une cible prometteuse dans la conception rationnelle de thérapies de la maladie. Celle-ci nécessite néanmoins une compréhension approfondie des propriétés structurales et dynamiques des deux partenaires moléculaires. Dans le cadre de cette thèse, nous avons étudié la structure de trois isoformes (E2, E3 et E4) de l’apoE par différentes techniques de biologie structurale et principalement par la réticulation chimique couplée à la spectrométrie de masse (CXMS) quantitative et par la bioinformatique structurale. Ces données complémentées par la spectroscopie infrarouge ont permis de construire des modèles structuraux de l’apoE2, E3 et E4. Nous avons mis en évidence l’interaction des domaines N- et C-terminal et la présence de multiples conformations de l’apoE chez les trois isoformes. Nos données suggèrent un équilibre entre deux principales conformations de l’apoE dont la population relative diffère entre les trois isoformes. Nous proposons les interfaces à cibler dans le cadre de thérapie visant à moduler les propriétés structurales des isoformes de l’apoE.Nous avons également mis en évidence que chaque isoforme d’apoE (E2, E3 et E4) interfère avec l’agrégation d’Aβ. Le peptide interagit avec les deux domaines N- et C- terminal de l’apoE. L’étude quantitative de l’interaction par CXMS a révélé des différences entre les cross-links formés en présence des isoformes. La modélisation du complexe apoE-Aβ a permis de mettre en évidence les interfaces impliquées dans l’interaction. Celle-ci possède une composante hydrophobe et électrostatique qui diffère chez les isoformes d’apoE. Nous proposons un mécanisme de l’interaction apoE-Aβ qui est initié par les propriétés hydrophobes des deux partenaires et qui est stabilisé par la suite via des contacts électrostatiques. Par ailleurs, une étude permettant d’explorer le potentiel de la nouvelle chimie de réticulation des résidues acides de protéine dans des applications en protéomique structurale a été effectuée. / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

La maladie d'Alzheimer (MA) est la forme la plus fréquente de démence chez les personnes âgées. L'une de ses caractéristiques est la formation extracellulaire de plaques séniles dans le cerveau des malades, composées du peptide Amyloïde-ß (Aß) sous forme agrégée et d'ions métalliques tels que le cuivre. Le peptide Aß forme un complexe avec les ions cuivre, capable de catalyser la formation d'espèces réactives de l'oxygène (ERO), en présence d'un réducteur tel que l'ascorbate. Ces espèces oxydantes sont délétères pour les molécules environnantes, ainsi que pour le peptide Aß lui-même. Etant proche du site de production des ERO, Aß est une cible privilégiée, notamment pour le radical hydroxyle HO*. L'objectif de ce travail a été d'étudier la réaction de production des ERO par le système Aß/Cu/ascorbate, de caractériser les dommages oxydatifs subis par Aß et d'évaluer les conséquences de l'oxydation de Aß sur la production des ERO, la coordination des ions métalliques et l'agrégation. Différentes techniques spectroscopiques ont été utilisées, notamment la spectrométrie de masse (MS), la spectroscopie de fluorescence, la résonnance paramagnétique électronique (RPE) et l'absorption de rayons X (XANES). Les sites d'oxydation du peptide Aß ont été étudiés par spectrométrie de masse (MS et MS/MS). Grâce à l'utilisation des outils de la protéomique et de la spectrométrie de masse à haute-résolution (HRMS), les acides aminés oxydés du peptide Aß ont été identifiés. Ainsi, Asp1, His13 et His14 sont les cibles privilégiées de l'attaque de HO*. Ce résultat était attendu puisque ces résidus sont impliqués dans la coordination du cuivre, par l'intermédiaire duquel les ERO sont directement générées. L'impact de l'oxydation du peptide sur la coordination des ions métalliques Cu(II), Cu(I) et Zn(II), la production de ERO ainsi que sur l'agrégation du peptide a été étudié. Les résultats ont montré que l'oxydation du peptide induit un changement de coordination du Zn(II) ainsi que des deux états d'oxydation du cuivre, menant à une augmentation de la production de ERO. De plus, l'oxydation de Aß a également un impact sur l'agrégation, ne privilégiant pas la formation de fibrilles. Le mode de coordination du complexe Cu-Aß lors de la production des ERO a été déduit de l'étude d'une série de peptides Aß comprenant un ou plusieurs acides aminés mutés. L'hypothèse proposant que les acides aminés oxydés sont ceux liés au cuivre lors de la production des ERO (Asp1, His13 et 14) a été renforcée, la mutation de Asp1 ou des deux His13 et 14 ayant un impact direct sur la production des ERO. Enfin, les effets pro- et anti-oxydants de l'ascorbate ont été étudiés, montrant que, sur le système Cu-Aß, l'ascorbate n'exerce ses propriétés anti-oxydantes qu'à forte concentration pour les molécules environnantes, mais qu'il n'a aucun effet protecteur sur le peptide Aß lui-même. / Alzheimer's Disease (AD) is the most frequent for of dementia in the elderly. A hallmark of AD is the extracellular formation of senile plaques in the brain of AD subjects, composed of the Amyloid-ß peptide (Aß) under aggregated form with metal ions such as copper ions. Aß can form a complex with copper ions, able to catalyze reactive oxygen species (ROS) formation in the presence of a reducing agent such as ascorbate. These oxidative species can oxidize the surrounding molecules and the Aß peptide itself. Being close to the production site of ROS, Aß is the preferential target, especially for the hydroxyl radical HO*. The aim of this work was to study the ROS production by the Aß/Cu/ascorbate system, to characterize the oxidation undergone by Aß and to evaluate the consequences of Aß oxidation on ROS production, metal ions coordination and aggregation. Several spectroscopic techniques have been used, in particular mass spectrometry (MS), fluorescence spectroscopy, electron paramagnetic resonance (EPR) and X-Ray absorption spectroscopy (XANES). The oxidation sites of Aß have been studied by mass spectrometry (MS and MS/MS). Thanks to the use of proteomic tools and high-resolution mass spectrometry (HRMS), the oxidized amino acid residues have been identified. Asp1, His 13 and His14 have been found to be the preferential targets for HO* on Aß. This result was expected as these residues are involved in copper coordination, from which the ROS are generated. The impact of Aß oxidation on Cu(II), Cu(I) and Zn(II) on metal ions coordination, on ROS production and on Aß aggregation has been studied. Results have shown that Aß oxidation induces a change of coordination of Zn(II) as well as Cu(II) and Cu(I), leading to an increase of ROS production. Moreover, Aß oxidation has also an impact on aggregation, as it does not favor fibrils formation. The Cu-Aß binding mode during ROS production has been deduced from the study of a series of mutated Aß peptides. The hypothesis, in which the amino acid residues bound to Cu during the ROS production are the oxidized one (Asp1, His 13 and His14) has been corroborated by the results of this study, the mutation of Asp1 or the two His having an impact on ROS production. Finally, the pro- and antioxidants effects of ascorbate have been investigated, showing that, on the Cu-Aß system, ascorbate only has antioxidant properties at high concentration for surrounding molecules, but does not exhibit any protecting effect on Aß itself.

Mon travail de thèse aborde différents développements physico-chimiques qui reposent sur le principe de transfert d'énergie par résonance de Foster (FRET). Le but est de parvenir à étudier et caractériser des assemblages moléculaires ainsi que des changements structurels de biomo-lécules (ou macro-ions) en phase gazeuse. Le transfert d'énergie par résonance de type Förster est un procédé par lequel de l'énergie s'échange de manière non radiative entre un chromo-phore dit donneur dans un état excité et un second chromophore accepteur en proximité di-recte. Conventionnellement, cette technique permet de localiser et déterminer l'écart entre deux molécules (de l'ordre de 10 à 100nm). Principalement utilisée pour étudier des systèmes biologiques, des résultats marquants ont été obtenus sur l'étude de système tel que l'appareil de Golgi, le cytosquelette ou les membranes cellulaires. Elle n'est cependant appliquée qu'à des systèmes en phase liquide. Il nous a paru intéressant de transposer cette technique en phase gazeuse, en utilisant la capacité des spectromètres de masse à sélectionner, isoler et activer des espèces moléculaires, nous permettant d'obtenir de nouvelles informations structurelles. Une grande partie de ma thèse a consisté à premièrement, valider le concept de FRET en phase gaz puis à développer et optimiser, la technique FRET dit ‘d'action'. L'Action-FRET est une tech-nique d'analyse par couplage de spectrométrie de masse et spectroscopie LASER mise au point par l'équipe Spectrobio afin d'étudier les molecules isolées en phase gazeuse. A travers ce dis-positif, je me suis particulièrement investi à contrôler, étudier et caractériser l'évolution des conformations de biomacromolécules d'intérêt biochimique et biologique. Dans une première partie je ferai une courte introduction générale sur les fondamentaux des protéines, de leur composition et élaboration en entités structurelles complexes, diverses et fonctionnelles. La manière dont les protéines s'arrangent successivement en niveaux structural quaternaire est aussi décrite. La deuxième partie est consacrée à une présentation des chromo-phores utilisés. Je présente ensuite leurs utilisations et détaille la synthèse des édifices molécu-laires produits pour réaliser les expériences de FRET. Ceux-ci sont constitués de composés bio-logiques (peptides ou protéines), couplés aux chromophores, (donneur-accepteur). Dans le contexte de ce chapitre se trouve également une discussion sur les mécanismes et produits uti-lisés lors de l'étape de conjugaison qui permet d'obtenir les composants désirés. En troisième partie vient un chapitre qui relate le fonctionnement des appareils utilisés dans le montage expérimental; le LASER et le spectromètre de masse. La méthode de couplage est dé-crite et spécifiée, détaillant comment les appareils commerciaux ont été modifiés pour interagir avec l'un avec l'autre. Avec ce nouveau montage, un suivi de la signature optique de FRET ap-partenant aux protéines entières greffées et à différents états de charge a été possible. Le quatrième chapitre est dédié dans les premières sections à la théorie et l'état de l'art en ce qui concerne le FRET. Les éléments emblématiques et leurs applications en solution de ces der-nières années et les travaux plus récents en phase gazeuse y sont présentés. Par ailleurs, nous avons voulu démontrer dans ce chapitre que nos diverses manipulations ont l'avantage critique de ne pas dépendre d'une mesure de l'émission de lumière suite au transfert résonant d'éner-gie. A la place, on dispose de la fragmentation spécifique de l'ion piégé du chromophore à tra-vers l'analyse de masse conventionnelle du spectromètre de masse pour détecter et quantifier une manifestation de FRET. Nous démontrerons aussi la possibilité cette méthode appliquée à la biologie moléculaire... [etc] / In this thesis, I discuss the application and development of mass spectrometry (MS) - LASER coupled techniques for the characterization and measurement of trapped biomolecules in the gas phase. In broad terms, this thesis demonstrates the potential and perspectives of action-FRET a novel structural biology tool amenable to the gas phase. The fundamentals rely on a well attested resonance quantic process known as Förster resonance energy transfer (FRET). As of yet it has been a widely utilized method to scrutinize molecular structure in solution. The mo-tivation has been to transpose this occurrence to the instrumental settings of a mass spectrom-eter, its gas confinement and, in doing so, overcome the earlier limitations of the technique and stride into the theoretical and experimental study of well determined systems as well as those whose structure were presently undetermined - all without the influence of the environment of a solvated medium. The first chapter of this thesis offers a general overview on peptides and proteins plus how they can be studied. Subsequent chapters include how the work carried out herein ads towards their study, moving the technique towards a gold standard of native mass spectrometry (native MS). In the second chapter, a treatment of the synthetic steps and preparations is given detailing the mechanistics of the reactions at play and above all outlining the experimental procedures and providing any information on any observations made. The third chapter describes, and is devoted to an introduction of the instrumental setup outlaid as it stands giving an account on the LASER, optical pieces and the mass spectrometer employed throughout the course of this thesis, effectively setting the premises of thought and understand-ing for subsequent chapters and methodology. Chapter four presents energy transfer, in particular to the Foster Resonance Energy Transfer and furthermore outlines the developed technique central to the mass spectrometry method to look at donor-acceptor chromophores espoused to biomolecular systems and their photofrag-ments — what is nicknamed as action-FRET. Chapter five reviews and discusses the study of a macromolecule: Ubiquitin, by action-FRET. The first gas phase experiment on the protein to have ever been realised. The information and content gathered from this adapted experiment is compared to work found elsewhere giving an appraisal on the potential of action-FRET and providing an idea to what future insights the technique could bring. In chapter six the reader is introduced to the project of establishing action-FRET in the negative mode of the mass spectrometer’s ionization source as opposed to its positive mode. Suitable pairs of donor-acceptor chromophores to validate the energy transfer under a negative regime were explored. These where profiled and characterized before being adapted to a biomolecular system. The results provide a different flavor of complimentary structural and conformation information, the first of its kind for negative mode action-FRET. The seventh and final chapter is devoted to future developments. The conclusive work tends to grant a further understanding of neurodegenerative diseases that afflict our societies. Chiefly that of the likes of Alzheimer’s: it’s the mechanism of action pertinent to other neurodegenera-tive pathologies; Parkinson’s, Huntington’s but also prion diseases or amyloid neuropathy. In doing so a contribution is presented on a way to trace a strategy in how to tackle and treat such diseases

Alzheimer's disease (AD) is characterised by a series of biomolecular aggregation events, which include the formation of neurotoxic protein structures composed of the β-amyloid (Aβ) peptide. In this thesis, fluorescence self-quenching (FSQ) between fluorescently-labelled peptides is introduced as a strategy for detecting and characterizing Aβ aggregates in solution, and for overcoming limitations associated with conventional methods. Using a combination of steady-state, picosecond time-resolved fluorescence and transmission electron microscopy, the fluorescence response of HiLyte Fluor 555-labelled Aβ peptides is characterised to demonstrate that Aβ self-assembly organizes the covalently attached probes in close proximity to trigger the self-quenching sensing process over a broad range of conditions. Importantly, N-terminal tagging of β-amyloid peptides is shown to not alter the self-assembly kinetics or the resulting aggregated structures. When performed in Förster resonance energy transfer (FRET) format, this method becomes a ratiometric platform to gain insights into amyloid structure and for standardizing in vitro studies of amyloid self-assembly. The ability of FSQ-based methods to monitor the inhibition of Aβ aggregation by model test compounds including the small heat shock protein (Hsp), the amyloid-binding alcohol dehydrogenase protein (ABAD) and bovine serum albumin (BSA) is also demonstrated. Given that Aβ is formed within the cell membrane and is known to induce its disruption, sophisticated single-molecule fluorescence spectroscopy methods were developed to quantify membrane dynamics induced by the presence of disrupting agents, such as Aβ and detergents. The solubilisation dynamics of single liposomes induced by the non-ionic surfactant Triton-X 100 (TX-100) were studied in real-time. Using this approach, the swelling and permeabilization steps of the solubilisation process were unambiguously separated within single FRET trajectories, and their kinetic details as a function of Triton-X 100 and presence of cholesterol within the membrane structure were examined. Finally, single-molecule stepwise-photobleaching techniques were employed to study the effect of Aβ oligomers interacting with supported-lipid bilayers, establishing a platform from which to investigate how the presence of a membrane layer affects Aβ oligomerization at the level of individual molecules. Overall, the fluorescence-based strategies for amyloid- and liposome-sensing presented in this work bridges the gap between current morphology-specific techniques and highly-specialized single-molecule methods to provide a biophysical toolbox to investigate the changes in structure, size and molecular interactions accompanying the amyloid aggregation pathway and for the screening of novel therapeutic and diagnostic agents.

Mutations of three genes encoding amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) have been shown to reliably result in familial early-onset Alzheimer's disease (FAD); a rare, but catastrophic, subtype of Alzheimer's disease (AD) marked by symptom emergence before age 65 as well as accelerated cognitive deterioration. The current study represents the first known meta-analysis on the association of APP, PSEN1 or PSEN2 on neurocognitive variables. A total of 278 FAD mutation-carriers (FAD-MC) and 284 cognitively healthy non-mutation-carriers (NC) across 10 independent investigations meeting inclusion criteria were chosen for the current meta-analysis (random effects design). Findings revealed an overarching trend of poorer performance by FAD-MC individuals compared to NC individuals across the majority of cognitive domains identified. Significant differences in effect sizes suggested FAD-MC individuals exhibited worse performance on measures of attention, explicit memory, fluency, primary memory, verbal, and visuospatial functioning. Findings indicative of differential sensitivity to cognitive domain impairments across FAD-MC and NC groups inform neuropsychological descriptions of individuals in preclinical phases of FAD.